PolyPeptide Group AG (PPGN) - Cash Flow Conversion Efficiency
Based on the latest financial reports, PolyPeptide Group AG (PPGN) has a cash flow conversion efficiency ratio of 0.150x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CHF49.66 Million ≈ $62.78 Million USD) by net assets (CHF330.99 Million ≈ $418.45 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
PolyPeptide Group AG - Cash Flow Conversion Efficiency Trend (2018–2024)
This chart illustrates how PolyPeptide Group AG's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read PolyPeptide Group AG (PPGN) financial obligations for a breakdown of total debt and financial obligations.
PolyPeptide Group AG Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of PolyPeptide Group AG ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
PennantPark Floating Rate Capital Ltd
NYSE:PFLT
|
-0.009x |
|
Hainan Haiyao Co Ltd
SHE:000566
|
-0.012x |
|
Formosa Taffeta Co Ltd
TW:1434
|
-0.003x |
|
Root Inc
NASDAQ:ROOT
|
0.021x |
|
Molinos Agro SA
BA:MOLA
|
-1.906x |
|
DL Holdings CO. LTD.
KO:000210
|
0.026x |
|
Gansu Guofang Gongmao(Grp)
SHG:601086
|
0.031x |
|
Tianjin Economic-technological Development Area Co Ltd
SHE:000652
|
0.044x |
Annual Cash Flow Conversion Efficiency for PolyPeptide Group AG (2018–2024)
The table below shows the annual cash flow conversion efficiency of PolyPeptide Group AG from 2018 to 2024. For the full company profile with market capitalisation and key ratios, see how much is PolyPeptide Group AG worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | CHF357.24 Million ≈ $451.65 Million |
CHF89.40 Million ≈ $113.02 Million |
0.250x | +161.48% |
| 2023-12-31 | CHF381.23 Million ≈ $481.97 Million |
CHF36.48 Million ≈ $46.13 Million |
0.096x | +639.13% |
| 2022-12-31 | CHF421.68 Million ≈ $533.11 Million |
CHF5.46 Million ≈ $6.90 Million |
0.013x | -90.49% |
| 2021-12-31 | CHF421.17 Million ≈ $532.48 Million |
CHF57.35 Million ≈ $72.51 Million |
0.136x | -51.11% |
| 2020-12-31 | CHF177.66 Million ≈ $224.61 Million |
CHF49.48 Million ≈ $62.56 Million |
0.279x | -25.15% |
| 2019-12-31 | CHF149.42 Million ≈ $188.90 Million |
CHF55.60 Million ≈ $70.29 Million |
0.372x | +139.51% |
| 2018-12-31 | CHF147.67 Million ≈ $186.70 Million |
CHF22.94 Million ≈ $29.01 Million |
0.155x | -- |
About PolyPeptide Group AG
PolyPeptide Group AG operates as a contract development and manufacturing company in Europe, the United States, and India. It develops and manufactures synthetic peptides and oligonucleotides used as active pharmaceutical ingredients or intermediates in therapeutic products for pharmaceutical and biotech companies. The company offers portfolio of drug therapies for metabolic diseases, including t… Read more